^
Chr t(11;14)
Multiple Myeloma
venetoclax
Sensitive: A2 - Guideline
Chr t(11;14)
Multiple Myeloma
VenVd
Sensitive: A2 - Guideline
Chr t(11;14)
Multiple Myeloma
venetoclax + bortezomib
Sensitive: B - Late Trials
Chr t(11;14)
Multiple Myeloma
TD
Resistant: B - Late Trials
Chr t(11;14)
Multiple Myeloma
VTD
Resistant: B - Late Trials
Chr t(11;14)
Multiple Myeloma
venetoclax + carfilzomib
Sensitive: C2 – Inclusion Criteria
Chr t(11;14)
Multiple Myeloma
VRD
Resistant: C3 – Early Trials
Chr t(11;14)
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
Chr t(11;14)
Multiple Myeloma
BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
Chr t(11;14)
Multiple Myeloma
BRAF inhibitor
Sensitive: C3 – Early Trials
Chr t(11;14)
Multiple Myeloma
venetoclax + atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
Chr t(11;14)
Multiple Myeloma
venetoclax + cobimetinib
Sensitive: C3 – Early Trials
Chr t(11;14)
Multiple Myeloma
venetoclax + daratumumab
Sensitive: C3 – Early Trials
Chr t(11;14)
Multiple Myeloma
venetoclax + bortezomib + daratumumab
Sensitive: C3 – Early Trials
Chr t(11;14)
Leukemia
DOT1L inhibitor + venetoclax
Sensitive: D – Preclinical
Chr t(11;14)
Multiple Myeloma
APG-2575
Sensitive: D – Preclinical